Healthcare (603313) 国投证券·2025-05-19 12:10Investment Rating - The investment rating for the company is "Buy-A" with a target price of 8.68 CNY, based on a 19x PE for 2025 [4][9][13]. Core Insights - The company has shown a significant recovery in profitability in Q1 2025, with a net profit of 0.59 billion CNY, a year-on-year increase of 196.22% [1][3]. - The company continues to pursue a global strategy, achieving a revenue of 84.49 billion CNY in 2024, a year-on-year growth of 5.94%, despite challenging economic conditions [2][9]. - The European market has been a standout performer, with overseas revenue reaching 67.50 billion CNY in 2024, up 6.68% year-on-year, and the company expects continued growth in this region [2][8]. Revenue and Profitability - In 2024, the company's revenue from mattress sales was 44.15 billion CNY, up 10.95% year-on-year, while other product lines showed mixed results [2][10]. - The gross margin for 2024 was 36.85%, a decrease of 1.50 percentage points year-on-year, but improved to 39.37% in Q1 2025 [3][11]. - The company anticipates revenue growth of 11.45%, 11.47%, and 10.30% for 2025, 2026, and 2027, respectively, with net profits projected to reach 2.61 billion CNY in 2025 [9][12][13]. Market Position and Strategy - The company is positioned as a leader in the domestic memory foam mattress market, focusing on global capacity expansion and brand internationalization [9][10]. - The impact of U.S. tariffs has been limited, and the company is leveraging its local production capabilities in the U.S. to enhance market share [8][9]. - The company plans to strengthen regional market development and channel construction to enhance competitiveness and drive stable growth in its ODM business [8][9].